


STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

| | |
|-------------------|----------------------------------|
| USAN | SEMAGACESTAT |
| PRONUNCIATION | sem" a gas' e stat |
| THERAPEUTIC CLAIM | Treatment of Alzheimer's disease |

CHEMICAL NAMES

1. Butanamide, 2-hydroxy-3-methyl-*N*-[(1*S*)-1-methyl-2-oxo-2-[[[(1*S*)-2,3,4,5-tetrahydro-3-methyl-2-oxo-1*H*-3-benzazepin-1-yl]amino]ethyl]-, (2*S*)-
2. (2*S*)-2-hydroxy-3-methyl-*N*-[(2*S*)-1-[[[(1*S*)-3-methyl-2-oxo-2,3,4,5-tetrahydro-1*H*-3-benzazepin-1-yl]amino}-1-oxopropan-2-yl]butanamide
3. *N*²-[(2*S*)-2-hydroxy-3-methylbutanoyl]-*N*¹-[(1*S*)-3-methyl-2-oxo-2,3,4,5-tetrahydro-1*H*-3-benzazepin-1-yl]-*L*-alaninamide
4. (*M*)-((*S*)-2-hydroxy-3-methyl-butyryl)-1-(*L*-alaninyl)-(*S*)-1-amino-3-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepin-2-one

STRUCTURAL FORMULA



| | |
|----------------------------|---|
| MOLECULAR FORMULA | C ₁₉ H ₂₇ N ₃ O ₄ |
| MOLECULAR WEIGHT | 361.4 |
| TRADEMARK | None as yet |
| MANUFACTURER | Eli Lilly and Company |
| CODE DESIGNATION | LY450139 |
| <u>CAS</u> REGISTRY NUMBER | 425386-60-3 |